TY - JOUR
T1 - Immunotherapy in Glioblastoma
T2 - An Overview of Current Status
AU - Sarfraz, Zouina
AU - Maharaj, Arun
AU - Venur, Vyshak Alva
AU - Lathia, Justin D
AU - Odia, Yazmin
AU - Ahluwalia, Manmeet S
N1 - © 2025 Sarfraz et al.
PY - 2025
Y1 - 2025
N2 - Glioblastoma (GB) is an aggressive brain tumor with standard therapies offering limited but measurable survival benefit. Immunotherapy is expanding the treatment landscape for GB. Immune checkpoint inhibitors (ICIs), including nivolumab and pembrolizumab, have shown benefit in several cancers and are being studied in GB, with ongoing efforts to address the tumor's immunosuppressive environment. Chimeric Antigen Receptor (CAR) T-cell therapies are also being explored, with new approaches designed to overcome antigen variability and improve access across the blood-brain barrier. Cancer vaccines, especially dendritic cell-based platforms like DCVax-L, have shown promising survival outcomes in clinical trials. Advances in biomarker analysis and genomics are supporting more personalized immunotherapy approaches. In addition, combination strategies involving ICIs, CAR T-cells, vaccines, and oncolytic viruses are being developed to enhance immune response. This review outlines current immunotherapy approaches in GB, focusing on their mechanisms, clinical development, and future directions.
AB - Glioblastoma (GB) is an aggressive brain tumor with standard therapies offering limited but measurable survival benefit. Immunotherapy is expanding the treatment landscape for GB. Immune checkpoint inhibitors (ICIs), including nivolumab and pembrolizumab, have shown benefit in several cancers and are being studied in GB, with ongoing efforts to address the tumor's immunosuppressive environment. Chimeric Antigen Receptor (CAR) T-cell therapies are also being explored, with new approaches designed to overcome antigen variability and improve access across the blood-brain barrier. Cancer vaccines, especially dendritic cell-based platforms like DCVax-L, have shown promising survival outcomes in clinical trials. Advances in biomarker analysis and genomics are supporting more personalized immunotherapy approaches. In addition, combination strategies involving ICIs, CAR T-cells, vaccines, and oncolytic viruses are being developed to enhance immune response. This review outlines current immunotherapy approaches in GB, focusing on their mechanisms, clinical development, and future directions.
U2 - 10.2147/CPAA.S497903
DO - 10.2147/CPAA.S497903
M3 - Review article
C2 - 40735070
SN - 1179-1438
VL - 17
SP - 185
EP - 209
JO - Clinical pharmacology : advances and applications
JF - Clinical pharmacology : advances and applications
ER -